Atea Pharmaceuticals (AVIR) Net Cash Flow: 2018-2024
Historic Net Cash Flow for Atea Pharmaceuticals (AVIR) over the last 7 years, with Dec 2024 value amounting to -$79.1 million.
- Atea Pharmaceuticals' Net Cash Flow rose 115.86% to $11.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$576.0 million, marking a year-over-year decrease of 573.39%. This contributed to the annual value of -$79.1 million for FY2024, which is 76.48% down from last year.
- Per Atea Pharmaceuticals' latest filing, its Net Cash Flow stood at -$79.1 million for FY2024, which was down 76.48% from -$44.8 million recorded in FY2023.
- Atea Pharmaceuticals' Net Cash Flow's 5-year high stood at $828.5 million during FY2020, with a 5-year trough of -$576.0 million in FY2022.
- Over the past 3 years, Atea Pharmaceuticals' median Net Cash Flow value was -$79.1 million (recorded in 2024), while the average stood at -$233.3 million.
- As far as peak fluctuations go, Atea Pharmaceuticals' Net Cash Flow soared by 6,556.68% in 2020, and later slumped by 573.36% in 2022.
- Over the past 5 years, Atea Pharmaceuticals' Net Cash Flow (Yearly) stood at $828.5 million in 2020, then slumped by 110.33% to -$85.5 million in 2021, then slumped by 573.36% to -$576.0 million in 2022, then soared by 92.22% to -$44.8 million in 2023, then slumped by 76.48% to -$79.1 million in 2024.